Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ
Market Cap
$618.63M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
18 of 809
Rank in Industry
15 of 445
Largest Insider Buys in Sector
OLMA Stock Price History Chart
OLMA Stock Performance
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Activity of Olema Pharmaceuticals, Inc.
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $22.85M and sold $22.6M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $33.34M and sold $7.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BVF PARTNERS L P/IL () — $281.55M. Graham G. Walmsley (director) — $20.61M. Paradigm Biocapital Advisors LP (10 percent owner) — $1.16M.
The last purchase of 100,000 shares for transaction amount of $1.16M was made by Paradigm Biocapital Advisors LP (10 percent owner) on 2023‑12‑06.
List of Insider Buy and Sell Transactions, Olema Pharmaceuticals, Inc.
| 2024-06-04 | Sale | Harmon Cyrus | director | 5,000 0.0079% | $12.33 | $61,650 | -11.23% | |
| 2024-06-04 | Sale | Graham G. Walmsley | director | 1.18M 2.2298% | $14.85 | $17.45M | -11.23% | |
| 2024-06-03 | Sale | Harmon Cyrus | director | 5,000 0.0083% | $10.93 | $54,650 | +5.77% | |
| 2024-05-31 | Sale | Harmon Cyrus | director | 15,000 0.0261% | $9.41 | $141,150 | +28.07% | |
| 2024-05-06 | Sale | Harmon Cyrus | director | 5,000 0.009% | $10.92 | $54,600 | +1.38% | |
| 2024-04-30 | Sale | Harmon Cyrus | director | 15,000 0.0251% | $9.51 | $142,650 | +5.70% | |
| 2024-03-28 | Sale | Harmon Cyrus | director | 20,000 0.0347% | $10.97 | $219,400 | -5.34% | |
| 2024-02-29 | Sale | Harmon Cyrus | director | 25,000 0.0455% | $12.41 | $310,309 | -11.65% | |
| 2024-02-01 | Sale | Harmon Cyrus | director | 5,000 0.0118% | $15.56 | $77,800 | -24.39% | |
| 2024-01-31 | Sale | Harmon Cyrus | director | 25,000 0.0463% | $12.23 | $305,750 | -11.50% | |
| 2023-12-29 | Sale | Harmon Cyrus | director | 25,000 0.0434% | $13.38 | $334,500 | -18.15% | |
| 2023-12-06 | Paradigm Biocapital Advisors LP | 10 percent owner | 100,000 0.1816% | $11.60 | $1.16M | -1.70% | ||
| 2023-12-05 | Graham G. Walmsley | director | 131,870 0.2639% | $14.19 | $1.87M | -10.35% | ||
| 2023-11-30 | Sale | Harmon Cyrus | director | 25,000 0.0412% | $12.57 | $314,250 | -16.93% | |
| 2023-11-22 | Sale | Harmon Cyrus | director | 3,989 0.0074% | $13.90 | $55,447 | -14.65% | |
| 2023-11-22 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 6,653 0.0123% | $13.89 | $92,410 | -14.65% | |
| 2023-11-22 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 9,145 0.0169% | $13.89 | $127,024 | -14.65% | |
| 2023-11-22 | Sale | Bohen Sean | PRESIDENT AND CEO | 27,932 0.0517% | $13.90 | $388,255 | -14.65% | |
| 2023-11-22 | Sale | Zojwalla Naseem | CHIEF MEDICAL OFFICER | 7,095 0.0131% | $13.89 | $98,550 | -14.65% | |
| 2023-11-21 | Sale | Harmon Cyrus | director | 4,192 0.008% | $14.86 | $62,293 | -17.73% |
Insider Historical Profitability
9.09%
| Paradigm Biocapital Advisors LP | 10 percent owner | 6590981 11.9625% | $11.06 | 1 | 0 | |
| BVF PARTNERS L P/IL | 4688954 8.5103% | $11.06 | 3 | 0 | <0.0001% | |
| Graham G. Walmsley | director | 700761 3.267% | $11.06 | 3 | 1 | <0.0001% |
| Harmon Cyrus | director | 781283 1.5814% | $11.06 | 0 | 29 | |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 574099 1.042% | $11.06 | 0 | 8 | |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 424987 0.7713% | $11.06 | 2 | 2 | +244.38% |
| Bohen Sean | PRESIDENT AND CEO | 144925 0.263% | $11.06 | 0 | 7 | |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | 30664 0.0557% | $11.06 | 0 | 2 | |
| Cormorant Asset Management, LP | 3270544 5.936% | $11.06 | 1 | 0 | <0.0001% | |
| LAMPERT MARK N | 2906659 5.2755% | $11.06 | 1 | 0 | <0.0001% | |
| Horn Kinney | CHIEF BUSINESS OFFICER | 2458 0.0045% | $11.06 | 0 | 10 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Bvf Inc Il | $103.42M | 16.33 | 9.14M | 0% | +$0 | 0.76 | |
| Paradigm BioCapital Advisors LP | $89.47M | 14.13 | 7.9M | 0% | +$0 | 3.25 | |
| Logos Global Management Lp | $49.63M | 7.84 | 4.38M | 0% | +$0 | 5.33 | |
| Deep Track Capital Lp | $36.51M | 5.77 | 3.23M | +67.04% | +$14.65M | 0.17 | |
| BlackRock | $36.41M | 5.75 | 3.22M | -1.45% | -$536,035.96 | <0.01 | |
| State Street | $35.98M | 5.68 | 3.18M | +372.16% | +$28.36M | <0.01 | |
| The Vanguard Group | $27.26M | 4.31 | 2.41M | -11.02% | -$3.38M | <0.01 | |
| Bioimpact Capital Llc | $22.12M | 3.49 | 1.95M | +5.2% | +$1.09M | 3.58 | |
| Dimensional Fund Advisors | $21.92M | 3.46 | 1.94M | +12.87% | +$2.5M | 0.01 | |
| Vivo Capital | $21.21M | 3.35 | 1.87M | 0% | +$0 | 1.87 | |
| Janus Henderson | $13.82M | 2.18 | 1.22M | +74.5% | +$5.9M | 0.01 | |
| Geode Capital Management | $9.5M | 1.5 | 839,345 | +1.76% | +$164,305.67 | <0.01 | |
| Wellington Management Company | $9.46M | 1.49 | 835,613 | +740.55% | +$8.33M | <0.01 | |
| Citadel Advisors LLC | $8.84M | 1.4 | 780,660 | +174.93% | +$5.62M | 0.01 | |
| Polar Capital | $8.49M | 1.34 | 750,000 | 0% | +$0 | 0.05 | |
| Woodline Partners LP | $8.49M | 1.34 | 750,279 | 0% | +$0 | 0.08 | |
| Braidwell Lp | $7.97M | 1.26 | 704,344 | New | +$7.97M | 0.45 | |
| Soleus Capital Management, L.P. | $7.45M | 1.18 | 658,000 | New | +$7.45M | 0.07 | |
| Victory Capital Management Inc | $6.91M | 1.09 | 610,649 | -1.75% | -$123,138.97 | 0.01 | |
| Altium Capital Management Lp | $6.85M | 1.08 | 605,000 | +46.27% | +$2.17M | 3.18 | |
| Ally Bridge Group | $6.33M | 1 | 559,035 | -15.17% | -$1.13M | 3.56 | |
| Marshall Wace | $6.2M | 0.98 | 547,803 | +88.43% | +$2.91M | 0.01 | |
| Silverarc Capital Management Llc | $5.83M | 0.92 | 515,317 | -10.2% | -$662,367.11 | 1.72 | |
| Morgan Stanley | $5.64M | 0.89 | 498,126 | +0.06% | +$3,192.24 | <0.0001 | |
| Adage Capital Partners Gp L L C | $5.21M | 0.82 | 460,000 | -8% | -$452,800.00 | 0.01 | |
| Goldman Sachs | $4.95M | 0.78 | 437,031 | +38.53% | +$1.38M | <0.01 | |
| Candriam S C A | $4M | 0.63 | 353,018 | +64.19% | +$1.56M | 0.03 | |
| Northern Trust | $3.95M | 0.62 | 349,157 | -1.04% | -$41,442.53 | <0.01 | |
| Bank of America | $3.7M | 0.58 | 326,819 | +714.81% | +$3.25M | <0.0001 | |
| Ameriprise Financial | $3.55M | 0.56 | 313,246 | +20.31% | +$598,703.53 | <0.01 | |
| Rafferty Asset Management Llc | $3.34M | 0.53 | 294,719 | New | +$3.34M | 0.01 | |
| Citigroup | $2.83M | 0.45 | 249,982 | +5,100.37% | +$2.78M | <0.01 | |
| Deutsche Bank | $2.82M | 0.45 | 249,030 | +0.15% | +$4,177.08 | <0.01 | |
| HighVista Strategies | $2.81M | 0.44 | 247,880 | 0% | +$0 | 1.03 | |
| Schonfeld Group | $2.31M | 0.36 | 203,825 | New | +$2.31M | 0.02 | |
| GHOST TREE CAPITAL LLC | $2.26M | 0.36 | 200,000 | New | +$2.26M | 0.74 | |
| UBS | $1.96M | 0.31 | 173,161 | +229.84% | +$1.37M | <0.01 | |
| Newtyn Management | $1.7M | 0.27 | 150,000 | 0% | +$0 | 0.37 | |
| Two Sigma Advisers LP | $1.68M | 0.27 | 148,500 | -17.86% | -$365,636.00 | <0.01 | |
| Sectoral Asset Management | $1.58M | 0.25 | 139,980 | +627.92% | +$1.37M | 0.66 | |
| Monashee Investment Management LLC | $1.53M | 0.24 | 135,000 | New | +$1.53M | 0.13 | |
| Voya Investment Management LLC | $1.47M | 0.23 | 129,587 | +1,067.35% | +$1.34M | <0.01 | |
| Verition Fund Management Llc | $1.38M | 0.22 | 122,178 | New | +$1.38M | 0.02 | |
| Acadian Asset Management | $1.17M | 0.18 | 103,179 | -59.68% | -$1.73M | <0.01 | |
| Nuveen | $1.14M | 0.18 | 100,889 | 0% | +$0 | <0.0001 | |
| Two Sigma | $1.08M | 0.17 | 95,814 | -42.18% | -$791,211.05 | <0.01 | |
| Atom Investors Lp | $1.07M | 0.17 | 94,321 | +60.22% | +$401,305.42 | 0.14 | |
| Millennium Management LLC | $999,069.00 | 0.16 | 88,257 | +1.15% | +$11,376.60 | <0.01 | |
| Charles Schwab | $984,353.00 | 0.16 | 86,957 | -2.53% | -$25,503.95 | <0.0001 | |
| BNY Mellon | $920,327.00 | 0.15 | 81,301 | -19.54% | -$223,468.04 | <0.0001 |